Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-B9) - Biotin
Katalog-Nummer LT7081-50
Size : 50µg
Marke : Leinco Technologies
AntiSARSCoV2 Nucleocapsid (N) (Clone NP1B9) – Biotin
AntiSARSCoV2 Nucleocapsid (N) (Clone NP1B9) – Biotin
Product No.: LT7081
Product No.LT7081 Clone NP1B9 Target SARSCoV2 Nucleocapsid (N) Product Type Recombinant Monoclonal Antibody Alternate Names COV2NP1B9, SARSCoV2 Nucleocapsid, SARSCoV2 Nucleoprotein, Protein N, SARSCoV N Protein Isotype Human IgG1 Applications ELISA |
Antibody DetailsProduct DetailsReactive Species SARSCoV2 ⋅ Virus Expression Host HEK293 Cells Immunogen SARSCoV2 Nucleocapsid (N) Protein Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 28°C. Do not freeze. Country of Origin USA Shipping Ships Overnight on Blue Ice RRIDAB_2894011 Applications and Recommended Usage? Quality Tested by Leinco ELISA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity AntiSARSCoV2 Nucleocapsid, clone NP1B9, specifically targets an epitope on the SARSCoV2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein. Background Severe acute respiratory syndrome coronavirus 2 (SARSCoV2), the causative agent of coronavirus disease 2019 (COVID19), is an enveloped, singlestranded, positivesense RNA virus belonging to the Coronaviridae family1. The SARSCoV2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. SARSCoV2 shares 79.6% identity with the original SARSCoV2. The N protein is 46 kDa and consists of two highly conserved structural domains, the Nterminal domain (NTD) and Cterminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and selfoligomerization3,4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7. The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARSCoV N protein9. Furthermore, antibodies9,10 and memory T cells11,12 targeting the N protein are identified in the sera of convalescent COVID19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic. Antigen Distribution The nucleocapsid protein is expressed in the internal nucleocapsid of SARSCoV2. NCBI Gene Bank ID Research Area COVID19 . Infectious Disease . Seasonal and Respiratory Infections . Viral . IVD Raw Material References & Citations1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020. 2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020. 3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020. 4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):5972. 2006. 5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):1384813855. 2005. 6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397405. 2008. 7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):1027610288. 2010. 8. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(45):206211. 2020. 9. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020. 10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020. 11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020. 12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971977.e3. 2020. 13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 14. 2020. |